Clinical trials: Eye Inflammation
Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
- Conditions
- Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation
- Trial name
- NCT01437982
- Testing
- Loteprednol Etabonate, Prednisolone Acetate 1% Oph Susp
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd.
- Trial name
- NCT03499873
- Testing
- Nepafenac 0.3% Oph Susp, Nepafenac 0.3% Oph Susp (reference)
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Actavis Inc.
Ocular Inflammation
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
- Trial name
- NCT00699153
- Testing
- Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation
Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of ISV-303 compared with DuraSite Vehicle.
- Trial name
- ISV-303 (NCT01576952)
- Testing
- ISV-303, DuraSite Vehicle
- Volunteers
- 268 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Retinitis Pigmentosa, Maculopathy, Age Related
High Resolution, High-speed Multimodal Ophthalmic Imaging
Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging.
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- IMA-MODE (NCT04129021)
- Testing
- High-resolution retinal imaging through adaptive optics, High-resolution retinal imaging through holographic systems
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ocular Surface Symptom, Ocular Surface Disease
Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024
The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface symptom of patients after PRK.
- Conditions
- Ocular Surface Symptom, Ocular Surface Disease, Eye Pain, Eye Inflammation
- Trial name
- NCT06624384
- Testing
- Group 1 drug, Group 3: Drug and palcebo
- Where
- Iran
- Volunteers
- 150 people
- Sponsor
- Mohsen Pourazizi
Cataract
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.
- Trial name
- PRO-145/III (NCT03693989)
- Testing
- Difluprednate 0.05%, Prednefrin
- Where
- 5 sites in Mexico
- Volunteers
- 178 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis
A double-blind study to evaluate the role of vitamin D in corneal epithelial barrier function, ocular microbiome, ocular inflammation, and visual acuity of children with allergic conjunctivitis.
- Trial name
- NCT05839938
- Testing
- Vitamin D
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Cataracts
VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery
The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%) ophthalmic solution in the prevention of…
- Trial name
- NCT01515826
- Testing
- Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel), Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
- Sponsor
- Alcon Research
Intraocular Inflammation, Intravitreal Injections
Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg
Aflibercept 8 mg is a high-concentration anti-vascular endothelial growth factor therapy developed to extend treatment intervals for retinal diseases while maintaining the efficacy and safety of aflibercept 2 mg.
- Trial name
- NCT07849309
- Testing
- Aflibercept (Eylea)
- Where
- Denmark
- Volunteers
- 3,690 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Anterior Uveitis (AU), Birdshot Chorioretinitis
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of…
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus
- Trial name
- NCT07065747
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Conjunctival Bacterial Flora
Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery
The purpose of this study is to determine whether additional topical application of 0.5% levofloxacin is more effective in reducing the load of the conjunctival bacterial flora in patients scheduled for intraocular surgery than…
- Trial name
- NCT00491049
- Testing
- 0.5% levofloxacin eye drops
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Cataract
Confirmatory Study Nepafenac 0.3%
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01109173
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle
- Where
- United States
- Volunteers
- 2,120 people
- Sponsor
- Alcon Research
Inflammation
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
- Trial name
- NCT00429923
- Testing
- Difluprednate
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- Sirion Therapeutics, Inc.
Cystoid Macular Edema
The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
This research is being done to look at the effects of an experimental drug called pegaptanib (also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that can occur…
- Trial name
- NCT00358423
- Testing
- Pegaptanib Sodium, Control
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Cataract, Ocular Inflammation
Safety and Effectiveness of Drop-free Small Incision Cataract Surgery
This is a randomized control trial comparing the effects of subconjunctival triamcinolone administration during surgery to topical prednisolone drops on the development of post-operative inflammation and macular edema in manual…
- Conditions
- Cataract, Ocular Inflammation, Ocular Hypertension, Post-Op Complication
- Trial name
- NCT05248139
- Testing
- Intraoperative delivery of medication, Kenalog (Triamcinolone), Topical post-operative eyedrops, Prednisolone acetate
- Volunteers
- 100 people
- Sponsor
- Visualiza
Ocular Melanoma
The Role of Inflammation in Ocular Tumours
This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: 1.
- Trial name
- NCT02909517
- Testing
- cSLO imaging
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Meibomian Gland Dysfunction (MGD)
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes.
- Trial name
- NCT07224529
- Testing
- Vevye(Cyclosporine 0.1% Ophthalmic Solution)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Alabama at Birmingham